Biopharmaceutical Company (Bayer subsidiary)
Appears in 1 story
Reported positive 36-month Phase I results; received Japan SAKIGAKE designation; enrolling patients in Phase III pivotal trial exPDite-2
For more than 50 years, Parkinson's disease treatment has meant managing symptoms with medication—not addressing the root cause: the death of dopamine-producing brain cells. Now, clinical trials are testing whether stem cell therapies can actually replace those lost neurons.
Updated May 27
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
